Comparison · NCT04333420-c10da378
Phase II: IFX-1 + BSC vs Phase II: BSC: Phase II: All-cause 28-day Mortality (FAS)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Phase II: IFX-1 + BSC vs Phase II: BSC: Phase II: All-cause 28-day Mortality (FAS). Trial comparisons, record NCT04333420-c10da378. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04333420-c10da378
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.133 | 0.0374 | 0.379 | wilson | |
| Risk in group 2 | 0.267 | 0.109 | 0.52 | wilson | |
| Risk difference, group 1 minus group 2 | -0.133 | -0.404 | 0.158 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.5 | 0.107 | 2.33 | log | |
| Odds ratio, group 1 over group 2 | 0.423 | 0.0647 | 2.77 | log | |
| Number needed to treat, for one fewer participant with the outcome on Phase II: IFX-1 + BSC than on Phase II: BSC | 7.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Phase II: IFX-1 + BSC | Phase II study part: IFX-1: 800mg intravenously administered, BSC: Best supportive care | 2 | 15 | OG000 |
| Group 2 | Phase II: BSC | Phase II study part: BSC: Best supportive care | 4 | 15 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Phase II: All-cause 28-day Mortality (FAS)
- Description
- Number and percentage of deaths (all-cause) until Day 28 (FAS)
- Time frame
- Day 28
- Population
- Full Analysis Set (FAS) including all randomized patients according to intention-to-treat principle.
Source ClinicalTrials.gov
Trial
- Title
- Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia
- NCT number
- NCT04333420
- Phases
- PHASE2, PHASE3
- Conditions
- Severe COVID-19 Pneumonia
- Interventions
- IFX-1 + BSC, BSC, IFX-1 + SOC, Placebo + SOC
- Lead sponsor
- InflaRx GmbH
- Results first posted
- 2023-06-05
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04333420?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04333420-c10da378